Ibrutinib treatment improves T cell number and function in CLL patients.
about
Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?Role of Bruton's tyrosine kinase in B cells and malignancies.A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD
P2860
Ibrutinib treatment improves T cell number and function in CLL patients.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Ibrutinib treatment improves T cell number and function in CLL patients.
@en
Ibrutinib treatment improves T cell number and function in CLL patients.
@nl
type
label
Ibrutinib treatment improves T cell number and function in CLL patients.
@en
Ibrutinib treatment improves T cell number and function in CLL patients.
@nl
prefLabel
Ibrutinib treatment improves T cell number and function in CLL patients.
@en
Ibrutinib treatment improves T cell number and function in CLL patients.
@nl
P2093
P2860
P356
P1476
Ibrutinib treatment improves T cell number and function in CLL patients.
@en
P2093
Amber Gordon
Amy J Johnson
Amy M Lehman
Bethany L Mundy
Carl H June
Carolyn Cheney
Farrukh Awan
Jeffrey A Jones
Jennifer A Woyach
Joseph A Fraietta
P2860
P304
P356
10.1172/JCI89756
P407
P50
P577
2017-07-17T00:00:00Z